Background-Experimentally, exogenous administration of recombinant stromal cell-derived factor-1␣ (SDF) enhances neovasculogenesis and cardiac function after myocardial infarction. Smaller analogs of SDF may provide translational advantages including enhanced stability and function, ease of synthesis, lower cost, and potential modulated delivery via engineered biomaterials. In this study, computational protein design was used to create a more efficient evolution of the native SDF protein. Methods and Results-Protein structure modeling was used to engineer an SDF polypeptide analog (engineered SDF analog [ESA]) that splices the N-terminus (activation and binding) and C-terminus (extracellular stabilization) with a diproline segment designed to limit the conformational flexibility of the peptide backbone and retain the relative orientation of these segments observed in the native structure of SDF. Endothelial progenitor cells (EPCs) in ESA gradient, assayed by Boyden chamber, showed significantly increased migration compared with both SDF and control gradients. EPC receptor activation was evaluated by quantification of phosphorylated AKT, and cells treated with ESA yielded significantly greater phosphorylated AKT levels than SDF and control cells. Angiogenic growth factor assays revealed a distinct increase in angiopoietin-1 expression in the ESA-and SDF-treated hearts. In addition, CD-1 mice (nϭ30) 
M ore people die annually of cardiovascular disease than of any other cause. The World Health Organization estimates that more than 17 million people per year die of cardiovascular disease. Of these deaths, an estimated 7.2 million were due to ischemic heart disease. An estimated 80 000 000 American adults (approximately 1 in 3) have at least 1 type of cardiovascular disease, with more than 22 000 000 having either coronary heart disease or heart failure. 1 Treatments for ischemic heart disease often fail because they do not address the underlying ventricular cellular pathophysiology and, most importantly, do not restore microvascular perfusion, which has been shown to be a critical, independent predictor of ventricular remodeling, as well as reinfarction, heart failure, and death. 2, 3 On the other hand, postinfarction patients who develop robust angiographic collateralization manifest improved regional ventricular function, which suggests an important role for the native revascularization process. 4 Current therapeutic options for ischemic heart disease are only capable of intervening in relatively large arteries, which leaves pervasive microvascular dysfunction unaddressed. This is important because microvascular integrity, specifically microvascular blood veloc-ity and flow, predicts functional recovery of ischemic myocardium. [5] [6] [7] [8] [9] In addition, current interventions are instituted relatively late in the overall time course of the disease process, with macrorevascularization possible in only 63% to 80% of patients with ischemic heart disease. 10 Even with reestablishment of epicardial coronary artery flow through thrombolysis, percutaneous intervention, or bypass grafting, a paucity of patent, functional microvasculature remains. Angiogenic cytokine therapy is a microrevascularization strategy that can serve as a primary therapy at any point in the disease process and can be used synergistically with traditional coronary revascularization methods. 11 A wide variety of cytokines and microrevascularization techniques have been used with varying degrees of success. [12] [13] [14] [15] Stromal cell-derived factor-1␣ (SDF) is a powerful chemoattractant and is considered to be one of the key regulators of hematopoietic stem cell trafficking between the peripheral circulation and bone marrow. It has been shown to effect proliferation and mobilization of endothelial progenitor cells (EPCs) to induce vasculogenesis and is significantly upregulated in response to both myocardial ischemia and infarction. 16, 17 SDF, a 67-amino acid protein, is also remarkably conserved among species; a single amino acid substitution is all that differentiates the human and murine sequences. 18 Experimentally, delivery of SDF to ischemic myocardium has been shown to increase circulating EPCs, significantly enhance myocardial EPC density, increase vasculogenesis, and augment myocardial function by enhancing perfusion, reversing cellular ischemia, increasing cardiomyocyte viability, and preserving ventricular geometry. 19, 20 However, exogenous SDF is quickly degraded by multiple proteases, 18, 21 has a large and complex tertiary structure that involves multiple disulfide linkages, 22 and is very expensive because it is a recombinant protein. Smaller analogs of SDF may provide translational advantages, including enhanced stability and function, ease of synthesis, lower cost, and potential modulated delivery via engineered biomaterials. 23, 24 In the present study, we set out to design and engineer a minimized, highly efficient polypeptide analog of the SDF molecule using computational molecular modeling and design. The primary design goal was to remove the large, central ␤-sheet region and link the native N-terminus (responsible for receptor activation and binding) and the C-terminus (responsible for extracellular stabilization) while maintaining functionality and the approximately perpendicular orientation between the 2 termini. 22 Two disulfide bonds located in the large central ␤-sheet region help to maintain the conformation of native SDF. To recover a similar conformation after excision of this portion of the protein, proline residue linkers were considered to connect the N-and C-termini. The cyclic proline residue limits the conformational space accessible to the polypeptide. Loop modeling calculations revealed the variability of conformations explored by linkers comprising different numbers of proline residues. A designed diproline linker yielded energetic and conformational advantages that resulted in a small, low-molecular-weight engineered SDF polypeptide analog (ESA) that was shown to have activity comparable to or better than recombinant human SDF both in vitro and in a murine model of ischemic heart failure.
Methods

Computational Protein Design, Modeling, and Synthesis
Loop modeling calculations were performed with the program MODELLER, which implements a loop modeling algorithm that consists of an optimization of a defined segment of protein structure in a fixed environment, guided by a pseudo-energy-scoring function. 25 Fifty different structures for a 1-, 2-, and 3-proline residue linker were created while constraining the coordinates of the remainder of the protein. The conformation with the lowest effective energy (best score) was analyzed with MolProbity, which provides detailed all-atom contact analysis of steric interactions, dihedral angles, and possible hydrogen bonds and van der Waals contacts. 26 After the amino acid sequence of the newly designed ESA peptide had been computationally designed and analyzed, it was synthesized by solid-phase peptide synthesis, which involves the incorporation of N ␣-amino acids into a peptide of any desired sequence with 1 end of the sequence remaining attached to a solid support matrix. After the desired sequence of amino acids has been obtained, the peptide is removed from the polymeric support.
Cell Isolation
Bone marrow mononuclear cells were isolated from the long bones of adult male green fluorescent protein (GFP)-expressing Wistar rats by density-gradient centrifugation with Histopaque 1083 (Sigma-Aldrich) and cultured in endothelial basal medium-2 supplemented with EGM-2 SingleQuot (Lonza) containing human epidermal growth factor, FBS, vascular endothelial growth factor, basic human fibroblast growth factor, recombinant human long R3 insulin-like growth factor-1, ascorbic acid, heparin, gentamicin, and amphotericin-B. The combination of endothelium-specific media and the removal of nonadherent bone marrow mononuclear cells was intended to select for the EPC phenotype.
Functional Characterization of Isolated EPCs by Boyden Chamber Assay
Boyden chambers (Neuro Probe) were used to assess EPC migration. Briefly, 8-m filters were loaded into control and experimental chambers. Fourteen-day EPCs cultured in endothelium-specific media on vitronectin-coated plates were trypsinized, counted, and brought to a concentration of 90 cells/L in Dulbecco phosphate buffered saline (DPBS). The bottom chamber of the control and experimental chambers were loaded with DPBS, 100 ng/mL recombinant SDF (R&D Systems) in DPBS, or 100 ng/mL ESA in DPBS. A 560-L cell suspension was added to the top chamber of each. All 3 chambers were incubated at 37°C, 5% CO 2 for 4 hours. The cells remaining in the top chamber were wiped clean with a cotton swab, and the filter was removed. Slides were visualized on a DF5000B Leica Fluorescent scope and analyzed via LASAF version 2.0.2 (Leica) software. Boyden chamber analysis was performed in triplicate. Additional Boyden chamber assays were run to generate a dose-response curve to compare molar equivalents of ESA and SDF. A series of progressively increasing ESA and SDF gradients (0.625, 1.25, 2.5, 5, 12.5, 20, 25, and 50 nmol/L) were used, and assays at each dose were run 10 times.
CXCR4 Receptor Activation Assay
Fourteen-day EPCs cultured in endothelium-specific media on vitronectin-coated plates were trypsinized and plated onto the bottom of a 96-well cell culture plate at a density of 10 000 cells per well and allowed to adhere for 24 hours. Cells were incubated with culture media that contained recombinant SDF (0.5 g/mL) or ESA (0.5 g/mL) or media only (control) for 10 minutes and subsequently were fixed in 4% formaldehyde. Phosphorylated and total AKT levels were quantified with the FACE AKT ELISA kit (Active Motif). These experiments were also repeated but with the addition of the chemokine receptor 4 (CXCR4) receptor antagonist AMD3100 to each experimental group. Results are reported in optical density (OD) units.
CXCR4 Receptor Expression
EPCs were seeded overnight at a density of 1ϫ10 4 cells per coverslip in 4-well slide chambers. Cells were either treated with 100 ng/mL SDF or 100 ng/mL ESA at 37°C for 6 hours. After chemokine stimulation, the cells were fixed and immunostained with rabbit anti-CXCR4 antibody (Abcam) at 1:250 for 12 hours. Cells were then incubated with Alexa 488 donkey anti-rabbit polyclonal antibody (Invitrogen) at 1:250 for 1 hour at room temperature. The cells were counterstained with DAPI to visualize nuclei. Immunofluorescence images were acquired with Zeiss ZEN 2010 software and a Zeiss LSM 710 confocal laser fluorescence scanning microscope.
Animal Care and Biosafety
Male CD-1 mice weighing 25 to 30 g were obtained from Charles River. Food and water were provided ad libitum. This investigation conformed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication No. 85-23, revised 1996) and was approved by the Institutional Animal Use and Care Committee of the University of Pennsylvania (protocol #709026).
Ischemic Cardiomyopathy Model
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg), intubated with a 22-gauge catheter, and mechanically ventilated (Hallowell EMC). With the animal supine, an anterior thoracotomy was performed in the left fourth intercostal space, and an 8-0 polypropylene suture was placed around the mid left anterior descending coronary artery (LAD) midway between the left atrial appendage and left ventricular (LV) apex and ligated to produce a large anterolateral myocardial infarction of 30% of the LV. The extent of infarction is highly reproducible in our hands, and progression to cardiomyopathy has been well documented. After ligation, animals were randomly assigned to receive direct intramyocardial injection into the peri-infarct border zone of either saline (30 L, nϭ7), SDF (6 g/kg in 30 L, nϭ13), or ESA (6 g/kg in 30 L, nϭ10). The thoracotomy was then closed, and the animals were extubated and recovered. Buprenorphine (0.5 mg/kg) was administered for postoperative analgesia. Both treatment groups received subcutaneous injections of 40 g/kg liquid sargramostim (granulocyte-macrophage colony-stimulating factor), diluted in saline for a total volume of 100 L, immediately postoperatively and on postoperative day 1.
In Vivo Angiogenic Growth Factor Expression
To assess upregulation of angiogenic growth factors and evaluate any potential sustained angiogenic effect of ESA treatment, hearts from all animals (control nϭ7, SDF nϭ13, and ESA nϭ10) were explanted 2 weeks after LAD ligation, and myocardial tissue biopsy samples were taken from the ischemic border zone. Samples were homogenized in T-Per tissue extraction reagent (Thermo-Fischer), normalized for total protein content via a Quick Start Bradford Protein Assay (Bio-Rad Laboratories), and tested for presence of mouse angiopoietin-1. Immunoblotting was performed with a mouse monoclonal antibody directed against mouse angiopoietin-1 (1:250; Abcam) and horseradish peroxidase-conjugated sheep anti-mouse IgG enhanced chemiluminescence secondary antibody (1:20 000; GE Healthcare). Chemiluminescent SuperSignal West Dura Extended Duration Substrate (Thermo Scientific) was used, and images were captured with a ChemiDoc XRSϩ system (Bio-Rad). Assays were performed in triplicate.
In Vivo Inflammatory Analysis
To assess upregulation of inflammatory factors, hearts from all animals (control nϭ7, SDF nϭ13, and ESA nϭ10) were explanted 2 weeks after LAD ligation, and myocardial tissue biopsy samples were taken from the ischemic border zone. Samples were homogenized in T-Per Tissue Extraction Reagent (Thermo-Fischer), normalized for total protein content via Quick Start Bradford Protein Assay (Bio-Rad), and tested for the presence of mouse tumor necrosis factor-␣. Immunoblotting was performed with a rabbit polyclonal antibody directed against mouse tumor necrosis factor-␣ (1:1000; Abcam) and horseradish peroxidase-conjugated sheep anti-rabbit IgG enhanced chemiluminescence secondary antibody (1:3000; GE Healthcare). Chemiluminescent SuperSignal West Dura Extended Duration Substrate (Thermo Scientific) was used, and images were captured with a ChemiDoc XRSϩ system (Bio-Rad).
To further assess the inflammatory response after treatment, hearts from a subset of animals (control nϭ4, SDF nϭ4, and ESA nϭ4) were explanted 2 weeks after LAD ligation, and myocardial tissue biopsy samples were taken from the ischemic border zone. Samples were homogenized in T-Per Tissue Extraction Reagent (ThermoFischer), normalized for total protein content via Quick Start Bradford Protein Assay (Bio-Rad), and tested for the presence of multiple inflammatory markers, including monocyte chemotactic protein-1, stem cell factor, nuclear factor (NF)-B, phospho-NF-B, phospho-p38 mitogen-activated protein kinase, phospho-Stat3, and phospho-IB-␣. Levels were quantified with the mouse inflammation ELISA strip (Signosis) and the PathScan Inflammation Multi-Target Sandwich ELISA (Cell Signaling Technology).
Echocardiographic Assessment of LV Geometry and Function
LV geometry and function were evaluated at 2 weeks (control nϭ7, SDF nϭ13, and ESA nϭ10) after LAD ligation with a highresolution (30 MHz) Vevo 770 transthoracic echocardiography system (VisualSonic Inc). Four equally spaced short-axis acquisitions and 1 maximum long-axis cine-loop acquisition of the LV were recorded with the ultrahigh-frame-rate EKVTM (ECG-based kilohertz visualization) acquisition mode. LV systolic function was evaluated by a modified 4-plane Simpson method. LV crosssectional areas were obtained by tracing the diastolic and systolic endocardial borders in each of the 4 equally spaced LV short-axis slices. On the basis of these measurements and the Simpson length (d, s), the fractional area change, ejection fraction, stroke volume, and cardiac output were computed with the Vevo 770 Standard Measurement Package. Before and during the ultrasound scanning, the mouse was lightly anesthetized with a mixture of 1% to 2% isoflurane gas and 100% oxygen and was placed in the supine position on a heating platform. All analyses were performed by a single investigator in a group-blinded fashion.
Statistical Analysis
Overall comparisons between the 3 groups were analyzed with a 1-way ANOVA. The results are reported with F (a ratio of the variance between groups to the variance within groups), 2 degrees of freedom, and the probability value. In addition, the unpaired Student t test was used to compare individual groups. Values are expressed as meanϮSEM. Statistical significance was defined by PՅ0.05.
Results
Computational Protein Design, Modeling, and Synthesis
The crystallographic structure of SDF at 2.2 Å resolution was used to guide design and modeling (Figure 1) . 27 The central ␤-sheet region residues (amino acids 18 to 54) were replaced with a 2-proline linker, which resulted in the 32-residue designed polypeptide ESA. The coordinates of residues 14FESHPPL20 were allowed to relax on modeling with MODELLER, whereas the coordinates of the remainder of the structure were constrained at their crystallographic values. Fifty different possible structures were generated for peptides with a 1-, 2-, or 3-proline linker. In general, the number of stable conformations increases substantially as the number of linking amino acids is increased (Figure 2 ). The peptide with the 2-proline linker (subsequently designated ESA) yielded energetic and conformational advantages. The ESA peptide S20 Circulation September 13, 2011 structure model with the lowest-scoring function was chosen for further analysis. Importantly, the 2-proline residues were found to have energetically favorable backbone dihedral angles ( and ) consistent with those observed for proline in natural protein structures (Figure 3 ). The introduction of a 2-consecutive-proline linker does not produce steric clashes within the modeled polypeptide structure. In addition, based on the calculated structure, phenylalanine 14 (F14 ESA ) interacts with glutamic acid 15 (E15 ESA ), histidine 17 (H17 ESA ), and leucine 20 (L20 ESA or L55 in SDF). These interactions are not present in the crystallographic structure of SDF, and this group of residues may form a small clusterlike structure that when coupled with the diproline spacer biases the peptide toward conformations similar to those found in native SDF (Figure 4) . Further structural analysis revealed that the model did not contain any steric clashes or unusual conformations of the backbone and the amino acid side chains.
EPCs Cultured in Endothelium-Specific Media Exhibit Enhanced Migration When Exposed to an ESA Gradient
Using a Boyden chamber assay, 14-day cells showed increased migration when placed in an ESA gradient compared with both recombinant SDF and saline (ESA 567Ϯ74 cells/ high-power field [ Figure 5 . In addition, a 1-way ANOVA was used to generate an overall comparison of the 3 study groups. EPC migration differed significantly across the 3 groups, F(2,6)ϭ41.27, Pϭ0.0003. A doseresponse curve generated by comparing molar equivalents of All of the residues from the ESA loop or linker region (F14, E15, S16, and L20) are located inside favored regions in the Ramachandran plots (bounded by the blue and purple lines), which indicate allowable bond angles. Most importantly, the 2-proline residues (P18 and P19) were found to have energetically favorable backbone dihedral angles ( and ) consistent with those observed in natural protein structures. Figure 6 ) demonstrated that ESA significantly outperformed SDF at the high end of the concentration range but was essentially equivalent to SDF for the low-and mid-range concentrations. Additionally, it was revealed that the effectiveness of ESA and SDF was not linearly correlated to the dose concentration and that there was a significant decrease in EPC migration at the highest doses for both.
ESA and SDF (
ESA Elicits Increased CXCR4 Receptor Activation In Vitro
Cells treated with ESA had greater levels of AKT phosphorylation than either recombinant SDF (1.638Ϯ0.239 versus 1.258Ϯ0.187 OD, Pϭ0.006) or control (1.638Ϯ0.239 versus 0.949Ϯ0.077 OD, Pϭ0.0003). There was no significant difference in total AKT content among the groups. In addition, a 1-way ANOVA was used to generate an overall comparison of the 3 study groups. Levels of AKT phosphorylation differed significantly among the 3 groups, F (2, 21) (Figure 7 ).
In Vivo Angiogenic Growth Factors Are Upregulated by ESA
At 2 weeks, immunoblotting revealed a significant quantitative increase in mouse angiopoietin-1 expression in the ESAand SDF-treated animals compared with the control group. Quantitative analysis demonstrated intensities of 336Ϯ9 (ESA), 367Ϯ17 (SDF), and 234Ϯ7 (control) intensity units, respectively (PϽ0.001). A representative immunoblot is shown in Figure 8 .
In Vivo Levels of Border-Zone Inflammatory Markers Are Not Statistically Different Between Groups
At 2 weeks, immunoblotting revealed similar levels of tumor necrosis factor-␣ among the ESA, SDF, and control groups. Quantitative analysis demonstrated intensities of 4784Ϯ274 SDF , E15 SDF , H17 SDF , and L55 SDF were absent in the crystallographic structure of SDF-1␣. These new interactions formed a small clusterlike structure that when coupled with the diproline spacer (yellow in ESA) may help to provide the necessary conformational stability and rigidity found in native SDF. Additional analysis demonstrated that after infarction and treatment, border-zone levels of the inflammatory factors monocyte chemotactic protein-1, stem cell factor, NF-B, phospho-NF-B, phospho-p38 mitogen-activated protein kinase, phospho-Stat3, and phospho-IB-␣ were either not significantly different or were significantly less in animals treated with ESA or SDF than in saline control animals. These findings indicate that inflammation is not responsible for the beneficial and proangiogenic effects of ESA.
Echocardiographic Assessment Demonstrates Enhanced LV Function After ESA Treatment
Echocardiographic assessment of cardiac function demonstrated significant benefits in the ESA group compared with the control group. At 2 weeks, ESA animals had a significantly improved ejection fraction (57Ϯ2.9% versus 42Ϯ1.6%, Pϭ0.002), cardiac output (30Ϯ1.8 versus 23Ϯ1.3 mL/min, Pϭ0.01), stroke volume (61Ϯ3.6 versus 48Ϯ2.9 L, Pϭ0.02), and fractional area change (52Ϯ3.6% versus 29Ϯ4.9%, Pϭ0.001) compared with controls. The ESAtreated mice also had a significantly increased fractional area change compared with SDF-treated mice (52Ϯ3.6% versus 42Ϯ3.2%, Pϭ0.04) and a strong trend toward improvement in all other ventricular function parameters assessed (Table) . A 1-way ANOVA was used to generate an overall comparison of the 3 study groups for each cardiac functional parameter. Values differed significantly across the 3 groups for ejection fraction (F (2, 27) 
Discussion
Angiogenic cytokine therapy for ischemic heart disease has proven to have great potential in numerous preclinical and clinical trials. The ability to replenish myocardial microvasculature could prove lifesaving to the millions of patients with myocardial ischemia. SDF, in particular, is among the most potent and specific angiogenic cytokines; its sole target, the CXCR4 cell surface antigen, is expressed in significant levels on CD34 ϩ EPCs, and expression of this receptor is related to efficient SDF-induced transendothelial migration. 28 SDF repeatedly has been shown to play a critical role in the rescue of myocardial function and stem cell recruitment to the heart after myocardial infarction. 19,20,29 -33 However, significant barriers remain between the diverse experimental successes of SDF angiogenic cytokine therapy and its widespread clinical translation. SDF is a large, complex 10-kDa protein that is expensive to manufacture and is readily inactivated by proteases that are upregulated at the time of myocardial infarction. 34, 35 It is our belief that smaller, synthetic analogs of SDF can provide translational advantages over the native protein, including enhanced stability and function, ease of synthesis, lower cost, and potential modulated delivery via engineered biomaterials. In the present study, we used advanced computational protein design techniques to create a more efficient and translatable molecule (ESA) evolved from the native SDF protein.
The ESA peptide was engineered to link the native N-terminus (responsible for receptor activation and binding) and the C-terminus (responsible for extracellular stabilization) with a diproline amino acid spacer. Although ESA may not have a well-defined tertiary structure, the linker is designed to bias the polypeptide toward structures that present the N-and C-termini in a manner similar to that present in the native SDF protein. On the basis of the modeled structure, F14
ESA is in proximity to E15 ESA , H17 ESA , and L20
ESA , forming a small cluster of side chains within ESA (Figure 4 ). These interactions, coupled with the diproline linker, may provide a conformational bias sufficient to recover the activity associated with SDF. The end product, ESA, is a novel polypeptide that contains less than half the number of amino acid residues, is less than half the molecular weight, and has enhanced physiological performance compared with recombinant SDF.
The SDF chemotactic homing mechanism is central to its ability to increase peri-infarct microvasculature and prevent mechanically inefficient ventricular contraction and eventual heart failure. Using a Boyden chamber assay to directly quantify the magnitude of cellular migration, we were able to demonstrate significantly enhanced migration of endothelial progenitor stem cells when placed in an ESA gradient compared with native SDF peptide. This result shows that for the same mass concentration, ESA not only retains this important function, despite its reengineered conformation, but surpasses the native protein. Compared with SDF, the relatively small size of ESA may enhance its diffusion potential and the speed at which the chemotactic signal is deployed. However, rapid diffusion is likely not the only factor that leads to significantly greater EPC migration. It has been shown that AKT activation is required for SDF-induced cellular migration. 36 To evaluate the EPC response to ESA, we incubated EPCs with culture media that contained ESA, recombinant SDF, or media only (control) and quantified both phosphorylated and total AKT levels by ELISA. In concordance with the results of the EPC migration assay, we were able to demonstrate significantly increased CXCR4 receptor activation and phosphorylated AKT levels in response to ESA compared with SDF. The addition of the CXCR4 antagonist AMD3100 eliminated this difference in receptor activation between ESA, SDF, and control, which confirms its receptor specificity. It is difficult to speculate which specific receptor-peptide interactions are responsible for the enhanced activation of CXCR4 by ESA, and future computational studies will be used to understand the surprisingly efficient activity of this novel polypeptide on a molecular level.
It is our belief that ESA, in a similar fashion to SDF, increases border-zone microvasculature, which in turn reverses cellular ischemia, preserves cardiomyocyte viability, and increases the mechanical efficiency of peri-infarct myocardium. In support of that hypothesis, we have shown that border-zone myocardium treated with ESA has significantly upregulated levels of angiopoietin-1, indicative of an ongoing angiogenic process as late as 2 weeks after infarction and treatment. One could argue that the mechanism responsible for the upregulated angiogenic activity is an exaggerated inflammatory response that results from the injection of ESA or even SDF. However, analysis of border-zone tumor necrosis factor-␣, monocyte chemotactic protein-1, stem cell factor, NF-B, phospho-NF-B, phospho-p38 mitogen-activated protein kinase, phospho-Stat3, and phospho-IB-␣ revealed that levels of inflammatory markers were not increased in experimental animals compared with controls, which indicates that the beneficial angiogenic and functional effects were not the result of differing levels of inflammation.
An increase in microvascular perfusion should result in decreased ventricular remodeling, improved regional ventricular function, and slower progression toward heart failure. Left ventricular geometry and function were evaluated at 2 weeks after LAD ligation with a high-resolution (30 MHz) transthoracic echocardiography system. The improved functionality of ESA in vitro was, once again, borne out in vivo. Animals treated with intramyocardial injections of the ESA peptide had better ejection fractions, cardiac output, stroke volume, and fractional area contraction than either the SDF or control group.
In conclusion, we have been able to engineer a novel, low-molecular-weight polypeptide with the enhanced physiological ability to induce EPC migration and EPC receptor activation and improve ventricular performance compared with native SDF. This peptide offers a more clinically translatable neovasculogenic therapy that could conceivably be deployed at any point in the time course of ischemic heart disease to address critical deficits in microvascular perfusion. 
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